Crescita Therapeutics™ Inc. Announces Acquisition of INTEGA Skin Sciences

PRNewswire: September 1, 2016 – MISSISSAUGA, Ontario, Canada – Crescita Therapeutics Inc. (TSX: CTX) (Crescita or the company), a drug development company that owns topical products for use in the treatment of medical conditions related to dermatology and pain, today announced that it has acquired INTEGA Skin Sciences Inc. (INTEGA), a Montreal-based dermatology company that develops, manufactures, sells, and markets science-based quality skin care products. INTEGA, financially backed by Knight Therapeutics (TSX: GUD) and Bloom Burton Healthcare Lending Trust, owns the Canadian distribution rights for a number of well-known and established skin care brands, including Laboratoire Dr. Renaud.

Key benefits of the transaction:

• Provides Crescita with a revenue-generating, fully integrated commercial skin care business, manufacturing facilities, and the capability to market prescription and over-the-counter (OTC) skin care products through established distribution channels;

• Provides Crescita with distribution rights to well-known and established skin care brands: Laboratoire Dr. Renaud, Pro-Derm, Premiology, and ISDIN;

• Provides Crescita with a commercial infrastructure capable of promoting its prescription drug Pliaglis in Canada;

• Allows Crescita to leverage its topical delivery technologies for the development of potential new OTC and/or prescription skin care products;

• Allows Crescita to leverage its business development capabilities to out-license INTEGA-owned brands outside Canada, including the United States; and

• Significant cash on hand in order to make additional acquisitions.

“With the acquisition of INTEGA, paid in Crescita common shares valued at $2.44 per share, Crescita becomes an integrated commercial skin care company while maintaining a strong balance sheet to finance our continued growth,” commented Dan Chicoine, Crescita’s chairman. “Our goal is to utilize the combined attributes of both businesses, in manufacturing, distribution, marketing, and research and development, to become a dominant player in the $15.0 billion Canadian and U.S. skin care industry.”

“I am thrilled to be integrating INTEGA into Crescita as the first step to becoming a leading dermatology specialty pharmaceutical company,” said Greg Orleski, founder and CEO of INTEGA.

Jonathan Goodman, CEO of Knight Therapeutics, added, “As shareholders of INTEGA and now Crescita, we are supportive of this acquisition. We believe that INTEGA’s established commercial brands and unique distribution capabilities combined with Crescita’s technology, experienced management, and strong balance sheet will facilitate accelerated organic growth and support future consolidation opportunities.”

Crescita (TSX: CTX) is a publicly traded Canadian drug development company that owns topical products for treating medical conditions in dermatology and pain. Crescita owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active drugs into or through the skin. Crescita’s board of directors and management team have demonstrated success in building Crescita’s predecessor company, Nuvo Research Inc., including developing multiple drugs that are now approved and commercialized and negotiating multiple licensing transactions. For additional information, please visit www.crescitatherapeutics.com.